Marinomed Biotech AG (WBO:MARI) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:MARI Marinomed Biotech AG WBO:MARI
43 GF Score
Price €5.90
GF Value €18.93
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Marinomed Biotech AG Quality Rank Related Terms

WBO:MARI
43GF Score
Marinomed Biotech AG WBO:MARI
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Marinomed Biotech AG (WBO:MARI) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €5.90 is trading 68.8% below its estimated GF Value™ of €18.93. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for WBO:MARI:

  • Quality Rank:
  • GF Value™: €18.93 vs. price of €5.90 (68.8% below fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the WBO:MARI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Marinomed Biotech AG Business Description

Other Exchanges 93Z:Germany
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
43GF Score

Get the complete analysis for WBO:MARI

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.90
Price
€18.93
GF Value